Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.
In the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by antibody-based microarrays, have during recent years been established as a proteomic to...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4944972?pdf=render |
| _version_ | 1819079802820231168 |
|---|---|
| author | Payam Delfani Linda Dexlin Mellby Malin Nordström Andreas Holmér Mattias Ohlsson Carl A K Borrebaeck Christer Wingren |
| author_facet | Payam Delfani Linda Dexlin Mellby Malin Nordström Andreas Holmér Mattias Ohlsson Carl A K Borrebaeck Christer Wingren |
| author_sort | Payam Delfani |
| collection | DOAJ |
| description | In the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by antibody-based microarrays, have during recent years been established as a proteomic tool providing unique opportunities for parallelized protein expression profiling. But despite the progress, several main technical features and assay procedures remains to be (fully) resolved. Among these issues, the handling of protein microarray data, i.e. the biostatistics parts, is one of the key features to solve. In this study, we have therefore further optimized, validated, and standardized our in-house designed recombinant antibody microarray technology platform. To this end, we addressed the main remaining technical issues (e.g. antibody quality, array production, sample labelling, and selected assay conditions) and most importantly key biostatistics subjects (e.g. array data pre-processing and biomarker panel condensation). This represents one of the first antibody array studies in which these key biostatistics subjects have been studied in detail. Here, we thus present the next generation of the recombinant antibody microarray technology platform designed for clinical immunoproteomics. |
| first_indexed | 2024-12-21T19:34:47Z |
| format | Article |
| id | doaj.art-d15ca39611574ddca30f98f01145851e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T19:34:47Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d15ca39611574ddca30f98f01145851e2022-12-21T18:52:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01117e015913810.1371/journal.pone.0159138Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.Payam DelfaniLinda Dexlin MellbyMalin NordströmAndreas HolmérMattias OhlssonCarl A K BorrebaeckChrister WingrenIn the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by antibody-based microarrays, have during recent years been established as a proteomic tool providing unique opportunities for parallelized protein expression profiling. But despite the progress, several main technical features and assay procedures remains to be (fully) resolved. Among these issues, the handling of protein microarray data, i.e. the biostatistics parts, is one of the key features to solve. In this study, we have therefore further optimized, validated, and standardized our in-house designed recombinant antibody microarray technology platform. To this end, we addressed the main remaining technical issues (e.g. antibody quality, array production, sample labelling, and selected assay conditions) and most importantly key biostatistics subjects (e.g. array data pre-processing and biomarker panel condensation). This represents one of the first antibody array studies in which these key biostatistics subjects have been studied in detail. Here, we thus present the next generation of the recombinant antibody microarray technology platform designed for clinical immunoproteomics.http://europepmc.org/articles/PMC4944972?pdf=render |
| spellingShingle | Payam Delfani Linda Dexlin Mellby Malin Nordström Andreas Holmér Mattias Ohlsson Carl A K Borrebaeck Christer Wingren Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics. PLoS ONE |
| title | Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics. |
| title_full | Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics. |
| title_fullStr | Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics. |
| title_full_unstemmed | Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics. |
| title_short | Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics. |
| title_sort | technical advances of the recombinant antibody microarray technology platform for clinical immunoproteomics |
| url | http://europepmc.org/articles/PMC4944972?pdf=render |
| work_keys_str_mv | AT payamdelfani technicaladvancesoftherecombinantantibodymicroarraytechnologyplatformforclinicalimmunoproteomics AT lindadexlinmellby technicaladvancesoftherecombinantantibodymicroarraytechnologyplatformforclinicalimmunoproteomics AT malinnordstrom technicaladvancesoftherecombinantantibodymicroarraytechnologyplatformforclinicalimmunoproteomics AT andreasholmer technicaladvancesoftherecombinantantibodymicroarraytechnologyplatformforclinicalimmunoproteomics AT mattiasohlsson technicaladvancesoftherecombinantantibodymicroarraytechnologyplatformforclinicalimmunoproteomics AT carlakborrebaeck technicaladvancesoftherecombinantantibodymicroarraytechnologyplatformforclinicalimmunoproteomics AT christerwingren technicaladvancesoftherecombinantantibodymicroarraytechnologyplatformforclinicalimmunoproteomics |